within Pharmacolibrary.Drugs.ATC.R;

model R05DB05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.3,
    Cl             = 0.00025,
    adminDuration  = 600,
    adminMass      = 30 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.003,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0006666666666666666,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R05DB05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Pentoxyverine is a non-opioid antitussive (cough suppressant) used for the symptomatic treatment of dry, irritating coughs. It has been marketed in several countries but is not widely approved or available in the United States or many European countries today, mainly replaced by newer or better-studied agents.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic studies describing model parameters in humans are available for pentoxyverine. The values below are not directly based on clinical studies but represent conservative estimates based on physicochemical properties and pharmacological class.</p><h4>References</h4><ol><li><p>Lin, MQ, et al., &amp; Liu, SW (2010). [Bioequivalence evaluation of orally disintegrating tablet of pentoxyverine citrate]. <i>Nan fang yi ke da xue xue bao = Journal of Southern Medical University</i> 30(7) 1621–1623. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20650784/&quot;>https://pubmed.ncbi.nlm.nih.gov/20650784</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R05DB05;
